Tagged with Oncology

Europe Speaking at the 2020 European Cancer Forum in Brussels, MSD’s Deepak Khanna outlines the progress that the company is making at the forefront of oncological innovation, the importance of multi-stakeholder collaboration, and the potential impact of a Europe-wide cancer plan.   As health stakeholders, we need to work across the…

Belgium The second edition of the European Cancer Forum was held in Brussels, Belgium on Tuesday, 29 January 2020. Hosted by MSD in collaboration with the European Cancer Patient Coalition (ECPC), Lung Cancer Europe (LuCE), and Digestive Cancers Europe (DiCE), the theme of this year’s event was “Towards A New Era…

China Dr Yuguang Wang, CEO of Maxinovel Pharmaceuticals, recaps his three decades of industry experience across Big Pharma, biotech and CRO organizations in China and the US, his motivation to establish Maxinovel Pharmaceuticals as a global, semi-virtual biotech, and their mission to develop a pipeline of orally-active one-pill combination of immuno-oncology…

Hungary Dr. Bodoky Gyorgy, founder and Honorary President of the Hungarian Society of Clinical Oncology (MKOT), explains the activities of the society, the multi-stakeholder collaborations MKOT has, the challenges of oncological treatments in Hungary, the impact of immunotherapy in oncology, and the future objectives of the society.   There needs to…

Czech Republic Emmanuelle Boishardy joined GSK in France 20 years ago. In 2017, she embarked on her first assignment as General Manager – in the Czech affiliate. She recounts how she adapted to her new position in a foreign country and turned the affiliate around by overhauling compliance processes and successful launches…

China Cancer is one of the world’s leading causes of death and in China, the globe’s most populous country, it is an ever-increasing concern. In 2018, there were approximately 4.3 million new cases of cancer in China, and this number is expected to increase to 6.7 million by 2040. Below, we…

China Hans Schmid, chairman; and Enrico Magnani, GM, of global cancer supportive care leader Helsinn Pharmaceuticals’ operations in China, share the Swiss company’s strategy in China, having entered in 2012; the milestone of launching their first product in China in November 2018 for chemotherapy-induced nausea and vomiting (CINV); the importance they…

Hungary István Peták, co-founder and CEO of Oncompass introduces the innovative start-up and elaborates on how its solution for digital treatment planning and digital biomarkers can revolutionize not only personalized oncology treatment for patients, but also be a key tool in accelerating the clinical development of new targeted therapies.   The…

China Speaking in May 2019, Dr Dajun Yang, chairman, executive director and CEO of Ascentage Pharma, shares the company’s top highlights over the past decade; their strong product pipeline and portfolio of innovative therapeutics focusing on protein-protein interactions (PPIs); and their global strategy to become an international, world-class biotech company.  …

Sweden Key stakeholders in Swedish pharma explain why Sweden’s record on cancer care is the best in Europe and what more still needs to be done.   National investments in cancer care have improved patient outcomes and reduced waiting times Malin Parkler, Pfizer With an estimated 18 million cases globally in…

UAE Khaled Elrefae, Middle East and Africa Specialty Care Operations Head (GM) for Ipsen, highlights Ipsen’s impressive internationalization strategy and the success factors as well as rationale behind the company entrance to the MEA market with the newly established affiliate in UAE. He then discusses his mandate to drive a transformation…

China With proactive government support and an increasingly specialised workforce, China has become one of the leading nations in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, along with the US. More than 200 CAR-T therapies are being developed in China, and the number of ongoing clinical trials continues to…